Formo Bio GmbH
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Formo Bio GmbH - overview
Established
2019
Location
Berlin, -, Germany
Primary Industry
Biotechnology
About
Based in Germany, Formo Bio GmbH specializes in innovative animal-free cheese alternatives produced through micro fermentation technology, catering to the evolving consumer demand for sustainable food choices. Formo Bio GmbH, founded in 2019 and headquartered in Berlin, Germany, focuses on creating animal-free cheese products. The company has undergone a strategic pivot towards developing sustainable dairy alternatives and has raised a total of EUR 61. 00 mn across multiple funding rounds, with the latest round being a VENTURE DEBT round of EUR 35.
00 mn on January 21, 2025. The founders include Eddy Yeh, Felipe Eing, Hsu Wei-Pin, and Raffael Wohlgensinger, with Raffael Wohlgensinger also serving as CEO alongside Nikolay Angelov. Formo has successfully completed 6 deals in its funding history. Formo specializes in producing animal-free cheese alternatives through innovative micro fermentation technology.
Their core product offerings include a diverse range of cheese alternatives, such as cream cheese substitutes and other varieties, designed to meet the growing demand for sustainable food choices. These products cater to individual consumers seeking plant-based options as well as food service businesses looking to incorporate sustainable dairy substitutes. Formo markets its products primarily in European countries, focusing on regions with high demand for plant-based food. In 2023, Formo reported no revenue, while also incurring an EBITDA loss of EUR 13,826,510.
60. The company generates revenue through direct sales to consumers and partnerships with retailers and food service providers, supplying its flagship animal-free cheese alternatives to grocery stores, restaurants, and catering businesses. This business model allows Formo to reach a wide client base while promoting sustainability in the food industry. In January 2025, Formo Bio GmbH raised EUR 35.
00 mn in VENTURE DEBT funding from the Future Food Fund in Japan. This investment will support the expansion of their animal-free product offerings across Europe, with plans to introduce new products designed for various dietary preferences. The funding will also facilitate the promotion of environmentally friendly food production techniques, aiming to strengthen their market presence and develop additional sustainable food alternatives.
Current Investors
Grazia Equity, Merck KGaA, Atlantic Food Labs
Primary Industry
Biotechnology
Sub Industries
Dairy Products, Other Food Products, Biotechnology
Website
www.eatformo.com
Verticals
Manufacturing
Company Stage
Series B
Total Amount Raised
Subscriber access only
Formo Bio GmbH - timeline of key events

Formo Bio GmbH - financials
| Fiscal Year Ended | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|
| Revenue (USD) | - | - | - |
| % Revenue Growth (YoY) | - | - | - |
| EBITDA (USD) | - | - | - |
| Operating Income (USD) | - | - | - |
| Operating Margin | - | - | - |
| % EBITDA Margin | - | - | - |
| NET Income (USD) | - | - | - |
| % Net Margin | - | - | - |
Formo Bio GmbH - employee data


Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.